New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
A look at big oncology deals since 2016 finds outright success stories hard to come by.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.